11,869 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Acquired by SG Americas Securities LLC

SG Americas Securities LLC bought a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,869 shares of the biotechnology company’s stock, valued at approximately $53,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Pacer Advisors Inc. increased its stake in Ironwood Pharmaceuticals by 26.6% during the third quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company’s stock worth $46,473,000 after acquiring an additional 2,372,183 shares during the last quarter. State Street Corp increased its stake in Ironwood Pharmaceuticals by 7.3% during the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after acquiring an additional 677,024 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Ironwood Pharmaceuticals by 23.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock worth $7,846,000 after acquiring an additional 364,841 shares during the last quarter. Stonepine Capital Management LLC increased its stake in Ironwood Pharmaceuticals by 1,982.8% during the third quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $4,120,000 after acquiring an additional 951,988 shares during the last quarter. Finally, Royce & Associates LP increased its stake in Ironwood Pharmaceuticals by 10.8% during the third quarter. Royce & Associates LP now owns 662,934 shares of the biotechnology company’s stock worth $2,731,000 after acquiring an additional 64,353 shares during the last quarter.

Analyst Upgrades and Downgrades

IRWD has been the subject of several recent analyst reports. Craig Hallum cut their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Finally, JMP Securities dropped their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research note on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Ironwood Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $10.67.

Ironwood Pharmaceuticals Trading Up 3.6 %

NASDAQ:IRWD opened at $2.01 on Friday. The firm has a market cap of $321.66 million, a PE ratio of -67.00 and a beta of 0.29. The stock has a fifty day moving average price of $3.60 and a 200 day moving average price of $4.17. Ironwood Pharmaceuticals, Inc. has a 12-month low of $1.59 and a 12-month high of $15.70.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the sale, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 208,742 shares of company stock worth $405,343. Company insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.